← All trials
NCT04347382
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- May 25, 2020
- Completion date
- May 30, 2020
- First posted
- Apr 15, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sheikh Zayed Medical CollegeLead sponsor
- Sheikh Zayed Medical CollegeReponsible party - principal investigator
- Sheikh Zayed Medical CollegeSponsor investigator
- Harvard UniversityStudy director
- Lahore Medical and Dental collegeOverall official - principal investigator
- Harvard UniversityStudy chair
- Mayo ClinicCollaborator
- Sheikh Zayed Medical CollegeOverall official - principal investigator
- University of Veterinary and Animal Sciences, LahoreStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.